OneMedNet's 1.5M-Patient Feed: Assessing Its Position on the Healthcare AI S-Curve

OneMedNet's latest delivery is a concrete validation of its growth engine. The company successfully handed over an anonymized data feed representing 1.5 million patients and 4 million encounters to a major analytics partner. This wasn't just a one-time transaction; it was delivered under OneMedNet's subscription model and served as a critical test for the recipient's platform. The feed's multimodal dataset, covering full patient journeys from notes to medications, proved the recipient's system could ingest and operationalize complex, real-world data at scale. For OneMedNet, this milestone directly supports its strategy of transitioning customers to predictable annual recurring revenue (ARR) streams.

This delivery arrives atop a period of explosive network growth. In just three months, the company's underlying data network has surged. Unique de-identified patient records increased 38% to over 47 million. That rapid expansion, alongside growth in provider sites and clinical exams, is building the fundamental infrastructure for these large-scale subscriptions. The company now operates what it calls the largest continuously refreshed, regulatory-grade Real-World Data network globally. This scale creates a powerful virtuous cycle: more data attracts more partners, whose validation projects drive further network growth and subscription commitments.

The market context for this growth is one of strong, sustained demand. The global real-world evidence solutions market is projected to grow at a CAGR exceeding 14.8% through 2030, reaching nearly $10.8 billion. This expansion is fueled by regulatory acceptance of real-world data and the need for faster, more efficient drug development. While established players like IQVIA and Optum dominate, the market is ripe for disruption by agile, AI-ready platforms.

The bottom line is that OneMedNet has hit a key inflection point. The 1.5-million-patient delivery proves its subscription model works for enterprise validation, while the network's 38% patient growth shows the underlying asset is scaling rapidly. The company is now positioned on the steep part of the adoption curve for healthcare AI data. Its long-term value will depend on capturing a meaningful share of that expanding $10.8 billion market, turning its validated network scale into durable, high-margin recurring revenue.

Financial Health and the Path to Recurring Revenue

The company's recent financial restructuring has cleared a major overhang, creating the stability needed to fund its growth. OneMedNet has slashed its debt burden by approximately 80%, reducing total liabilities from $19.7 million at the end of 2024 to $6.2 million by June 2025. This dramatic improvement came through a combination of debt conversions, vendor repayments, and highly discounted settlements. The move not only strengthens the balance sheet but also frees up capital for strategic investment.

This financial stabilization is now directly fueling the core growth engine: the subscription strategy. Earlier in 2025, the company reported an 815% increase in bookings, a staggering acceleration that signals strong market validation. That momentum is being operationalized through a critical partnership. OneMedNet has selected Palantir Technologies to provide the AI analytics infrastructure for its iRWD™ platform. This isn't just a tech upgrade; it's the foundational layer that allows OneMedNet to monetize its massive data network at scale. Palantir's platform enables faster data discovery, accurate cohort creation, and conversational search, turning raw data into actionable, high-value subscriptions.

The connection between these points is clear. The financial health provides the runway. The subscription momentum shows the market is ready. And the Palantir partnership provides the technological engine to deliver that value efficiently. Together, they form a coherent path from a restructured balance sheet to a scalable, recurring revenue model powered by the largest continuously refreshed RWD network. The company is now positioned to capture a larger share of the growing real-world evidence market, with the financial and technological infrastructure to support it.

Catalysts, Risks, and the Infrastructure Play

OneMedNet is building the foundational data layer for the next paradigm in healthcare. Its success now hinges on a few critical catalysts and the execution to convert its massive network into durable value. The most immediate catalyst is the integration of its data into AI/ML workflows for drug development. While not a direct partnership, the company's validated network is the essential input for the kind of precision medicine platforms being built by players like Tempus. Tempus's integration with Flatiron Health to embed genomic testing into oncology workflows is a clear signal of where the industry is headed. OneMedNet's multimodal, continuously refreshed data feed is the raw material that powers such systems. The company's strategic position is to be the trusted, regulatory-grade data provider enabling these next-generation AI applications.

Yet the path from infrastructure to revenue is fraught with execution risk. The company has demonstrated it can build a large network and secure a major subscription. The next, harder step is scaling that model to generate predictable, high-margin recurring revenue. This requires converting its asset base into a steady stream of ARR across more partners and use cases. The risk is that the operational complexity of managing a 47-million-patient network and its partnerships could outpace the company's ability to monetize it efficiently. Execution will determine whether the network's scale translates into market dominance or remains a costly asset.

To diversify its revenue and reduce concentration risk, OneMedNet is pursuing a strategic expansion into healthcare data annotation. The company recently partnered with Medcase, a network of healthcare professionals, to enter this market. The global healthcare data annotation market is projected to grow from $1.5 billion in 2025 to $2.8 billion by 2030. This move is a classic infrastructure play: by combining its iRWD™ platform with expert annotation services, OneMedNet aims to capture a higher-value segment of the AI training data supply chain. It creates a complementary revenue stream that leverages its existing network and regulatory expertise.

The bottom line is that OneMedNet is positioned at the base of the healthcare AI S-curve. It has built the fundamental rails. The company's future depends on its ability to execute on the integration catalysts, manage the operational risk of scaling its network, and successfully diversify into adjacent high-growth markets like data annotation. If it navigates these challenges, it will be a key beneficiary of the paradigm shift. If not, its valuable infrastructure may fail to reach its full exponential potential.